Mechanistic Insights from a Phase 2a Study with MH002, an Optimised Consortia Therapeutic Evaluated in Ulcerative Colitis Patients
Time: 12:45 pm
day: Day 1 Track A AM
Details:
- Outlining MH002, a 6-strain consortia therapeutic designed, optimised and manufactured through MRM Health’s CORAL® technology, the most advanced live biotherapeutic in clinical development for Ulcerative Colitis and Pouchitis
- Receiving first-time insight on the translation of the mechanism of action of MH002 in activity in Ulcerative Colitis patients – results from a placebo-controlled randomized Phase 2a study
